Systematic Review on Clinical Efficacy of Compound Glycyrrhizin in the Treatment of Fatty Liver

XU Yuan; GOU Xiaojun; CAO Shan

doi:10.14009/j.issn.1672-2124.2022.05.020

您当前的位置：

首页 >

文章列表页 >

Systematic Review on Clinical Efficacy of Compound Glycyrrhizin in the Treatment of Fatty Liver

更新时间：2022-10-08

- Systematic Review on Clinical Efficacy of Compound Glycyrrhizin in the Treatment of Fatty Liver
- Vol. 22, Issue 5, Pages: 603-607(2022)
- 作者机构：
  
  1. 陕西中医药大学药学院
  2. 上海市宝山区中西医结合医院中心实验室
  3. 上海市宝山区中西医结合医院药剂科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.05.020
  CLC： R259
- Published：2022，
扫描看全文
XU Yuan, GOU Xiaojun, CAO Shan. Systematic Review on Clinical Efficacy of Compound Glycyrrhizin in the Treatment of Fatty Liver. [J]. 22(5):603-607(2022)
DOI：

XU Yuan, GOU Xiaojun, CAO Shan. Systematic Review on Clinical Efficacy of Compound Glycyrrhizin in the Treatment of Fatty Liver. [J]. 22(5):603-607(2022) DOI： 10.14009/j.issn.1672-2124.2022.05.020.

摘要

目的：系统评价复方甘草酸苷治疗脂肪肝的临床疗效。方法：检索PubMed、the Cochrane Library、Embase、中国知网、万方数据库和维普数据库，检索2021年11月前发表的复方甘草酸苷治疗脂肪肝的随机对照试验(研究组患者采用复方甘草酸苷+其他治疗，对照组患者采用除复方甘草酸苷外的其他方法治疗)

采用RevMan 5.3软件进行Meta分析。结果：纳入9篇文献，共795例受试者，其中研究组400例，对照组395例。Meta分析结果显示，研究组患者的临床有效率明显高于对照组(OR=6.35

95%CI=4.00～10.07

Z=7.85

P<0.000 01)

天冬氨酸转氨酶(MD=-31.88

95%CI=-51.14～-12.62

Z=3.24

P=0.001)、丙氨酸转氨酶(非酒精性脂肪性肝病亚组：MD=-14.68

95%CI=-18.15～-11.22

Z=8.30

P<0.000 01;酒精性脂肪性肝病亚组：MD=-29.52

95%CI=-30.77～-28.28

Z=46.36

P<0.000 01)和三酰甘油(MD=-0.73

95%CI=-1.19～-0.27

Z=3.10

P=0.002)等指标水平明显低于对照组，上述差异均有统计学意义。两组患者不良反应发生情况的差异无统计学意义(OR=0.38

95%CI=0.14～1.03

Z=1.91

P=0.06>0.05)。结论：复方甘草酸苷治疗脂肪肝具有良好的有效率和较高的安全性。

Abstract

OBJECTIVE: To systematically evaluate the clinical efficacy of compound glycyrrhizin in the treatment of fatty liver. METHODS: PubMed

the Cochrane Library

Embase

CNKI

Wanfang Data and VIP database were retrieved to collect the randomized controlled trials（RCT） of compound glycyrrhizin in the treatment of fatty liver（the study group was treated with compound glycyrrhizin + other treatments

while the control group received other treatments except for compound glycyrrhizin） till Nov. 2021. Meta-analysis was performed by using RevMan 5.3 software. RESULTS: Nine articles with a total of 795 patients were extracted

including 400 cases in the study group and 395 cases in the control group. Meta-analysis results showed that the clinical effective rate in the study group was significantly higher than that in the control group（OR=6.35

95%CI=4.00-10.07

Z=7.85

P<0.000 01）

AST（MD=-31.88

95%CI=-51.14--12.62

Z=3.24

P=0.001）

ALT（non-alcoholic fatty liver disease subgroup: MD=-14.68

95%CI=-18.15--11.22

Z=8.30

P<0.000 01; alcoholic fatty liver disease subgroup: MD=-29.52

95%CI=-30.77--28.28

Z=46.36

P<0.000 01） and TG（MD=-0.73

95%CI=-1.19--0.27

Z=3.10

P=0.002） were significantly lower than those in the control group

the differences were statistically significant. There was no statistical significance in the incidence of adverse drug reactions between two groups（OR=0.38

95%CI=0.14-1.03

Z=1.91

P=0.06>0.05）. CONCLUSIONS: Compound glycyrrhizin has better efficacy and higher safety in the treatment of fatty liver.

关键词

复方甘草酸苷脂肪肝Meta分析

Keywords

Compound glycyrrhizinFatty liverMeta-analysis

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Systematic Review of Efficacy and Safety of Silibinin Capsules and Hugan Tablets in Improving Fatty Liver-Related Biochemical Indicators

Systematic Review on Efficacy and Safety of Compound Glycyrrhizin Combined with Cimetidine in the Treatment of Henoch-Schonlein Purpura in Children

Systematic Review on Compound Glycyrrhizin Combined with Reduced Glutathione in the Treatment of Alcoholic Cirrhosis

Systematic Review of Huisheng Oral Liquid on Coagulation Function, Efficacy and Safety of Patients with Non-Small Cell Lung Cancer

Systematic Review of Efficacy and Safety of Dantian Jiangzhi Pills Combined with Statins in the Treatment of Hyperlipidemia

Related Author

潘慧杰

张碧华

王洋

李琼

郑宇静

郑子恢

张亚同

PENG Jia

Related Institution

Beijing Hospital

北京医院药学部国家老年医学中心中国医学科学院老年医学研究院北京市药物临床风险与个体化应用评价重点实验室(北京医院)

Dept.of Pharmacy, the Third Hospital of Changsha

Changsha Institution of Clinical Application Research on Antibiotics

Dept. of Hepatobiliary Surgery,the Second Affiliated Hospital of Army Medical University of PLA

⁰